BEIZRAY (Docetaxel) Patent Expiration, LOE Window & CMS Spending

BEIZRAY (Docetaxel) by Zhuhai Beihai Biotech: FDA Orange Book core substance LOE 2036-05-16, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $7,920 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorZhuhai Beihai Biotech
FDA Application & PathwayN218711 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-05-16
Last Listed Patent or Exclusivity Date2036-05-16
Orange Book Patents (*PED Extensions)22 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($7,920 intro WAC)